Importantly, these studies are supported by clinical data showing a negative correlation between eEF2K expression and patient prognosis in medulloblastoma, glioblastoma multiforme (Leprivier et al., 2013) and breast cancer (Table 1). This evidence concerns the gene EEF2K and breast carcinoma.